Article
Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity.
Seminars in oncology - 1 Dec 2000
Chien K R
Abstract excerpt
Recent clinical studies have documented the efficacy of trastuzumab (Herceptin; Genentech, Inc, South San Francisco, CA) as a new biologically targeted therapy for erbB-2 receptor-positive forms of breast cancer. During the course of a large-scale clinical trial, a subset of patients reported the onset of symptoms and signs of cardiac failure that appeared to be aggravated by concomitant exposure to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.